SIGA Technologies


Developer of small-molecule antiviral medicines and related countermeasures focused on orthopoxviruses and other high-concern infectious diseases. Operates product development, preclinical and clinical safety testing, regulatory submissions across multiple jurisdictions, and manufacturing/packaging operations to supply government stockpiles and healthcare providers. Collaborates with U.S. government agencies and international regulators on development and procurement.

Industries

Biotechnology
Biotech & Pharmaceuticals
Pharmaceutical and biotechnology

Nr. of Employees

medium (51-250)

SIGA Technologies

New York, New York, United States


Patents

Polymorphic forms of ST-246 and methods of preparation

US-12433868-B2

View Details

Polymorphic forms of ST-246 and methods of preparation

US-11890270-B2

View Details

ST-246 (tecovirimat monohydrate) suspension formulations

US-11779566-B2

View Details

ST-246 (tecovirimat monohydrate) suspension formulations

US-11433051-B2

View Details

Polymorphic forms of ST-246 and methods of preparation

US-10933050-B2

View Details

ST-246 liquid formulations and methods

US-10864282-B2

View Details
View All Patents

Products

TPOXX (tecovirimat)

A small-molecule antiviral indicated for treatment of smallpox and authorized/approved for use against certain orthopoxvirus infections; available as oral capsules and an intravenous formulation, with pediatric liquid suspension under development.

TPOXX

Oral TPOXX (tecovirimat capsule) is an antiviral drug indicated for treating smallpox disease, and used under expanded access for mpox, specifically inhibiting the orthopoxvirus VP37 protein.


Services

Collaborative development arrangements with public agencies and funders to advance medical countermeasures and support procurement to national stockpiles.

Expertise Areas

  • Antiviral drug development
  • Preclinical animal model development
  • Clinical safety studies and expanded-access protocols
  • Regulatory strategy and multi-jurisdictional approvals
  • Show More (4)

Key Technologies

  • Small-molecule antiviral therapeutics
  • Orthopoxvirus animal models (for efficacy testing)
  • Formulation chemistry (oral capsules, IV, liquid suspension)
  • In vitro antiviral assays / drug screening
  • Show More (2)

News & Updates

Oral tecovirimat capsules were approved by the U.S. FDA specifically for treatment of smallpox disease in adults and pediatric patients weighing at least 13 kg.

Oral tecovirimat authorized by Health Canada for treatment of smallpox in adults and pediatric patients weighing at least 13 kg.

Tecovirimat approved by the European Medicines Agency for treatment of smallpox, cowpox, and vaccinia complications in specified populations.

Tecovirimat capsules approved by Japan's Pharmaceuticals and Medical Devices Agency for treatment of orthopoxvirus infections including mpox and smallpox in adults and pediatric patients weighing at least 13 kg.

Product advanced to the Strategic National Stockpile and procured under Project BioShield and other government programs.

Company reports cumulative government procurement orders above $1 billion.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.